Active, not recruitingPhase 2NCT04651634
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MitoImmune Therapeutics
- Principal Investigator
- Jinsang Jung, M.PharmMitoImmune Therapeutics
- Intervention
- MIT-001 plus CCRT(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (16)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Cancer Center of Kansas, Wichita, Kansas, United States
- James P. Wilmot Cancer Center, Rochester, New York, United States
- Wake Forest Baptist Health - Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
- James Cancer Hospital Solove Research Institute, Columbus, Ohio, United States
- The Catholic University of Korea Saint Vincent's Hospital, Suwon, Gyeonggi-do, South Korea
- Jeonbuk National University Hospital, Jeonju, Jeollabuk-do, South Korea
- Keimyung University Dongsan Hospital, Daegu, South Korea
- Chungnam National University Hospital, Daejeon, South Korea
- National Cancer Center, Goyang-si, South Korea
- Seoul National University Bundang Hospital, Gyeonggi-do, South Korea
- Inha University Hospital, Incheon, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Korea University Guro Hospital, Seoul, South Korea
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04651634 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →